J INTS BIO | MedPath

J INTS BIO's JIN-A02 Shows Promise in EGFR-TKI Resistant NSCLC

7 months ago

• J INTS BIO presented interim Phase 1/2 data for JIN-A02, a 4th-generation EGFR-TKI, at the ENA Symposium, targeting resistant NSCLC. • The trial showed JIN-A02 has a favorable safety profile with no dose-limiting toxicities up to 150mg daily in EGFR-mutated NSCLC patients. • Early efficacy signals included tumor control and partial responses in lung lesions, along with activity against brain metastases, were observed. • JIN-A02 could address a critical unmet need in NSCLC patients who have developed resistance to 3rd-generation EGFR-TKIs.